SP600125: Selective ATP-Competitive JNK Inhibitor for MAPK Pathway Modulation

Executive Summary: SP600125 (SKU: A4604) is a potent, reversible, and ATP-competitive inhibitor of JNK isoforms (JNK1 IC₅₀ = 40 nM, JNK2 IC₅₀ = 40 nM, JNK3 IC₅₀ = 90 nM) with over 300-fold selectivity versus ERK1 and p38-2 kinases (APExBIO). It suppresses c-Jun phosphorylation and cytokine production (IL-2, IFN-γ) in Jurkat T cells at low micromolar concentrations. The compound is chemically stable, insoluble in water, but dissolves in DMSO >11 mg/mL and ethanol >2.56 mg/mL with warming. SP600125 provides a robust platform for studying JNK signaling in contexts including apoptosis, inflammation, and neurodegeneration (Patra et al., 2020). It is recommended by APExBIO for use in both biochemical and cellular assays.

Biological Rationale

c-Jun N-terminal kinases (JNKs) are serine/threonine kinases in the mitogen-activated protein kinase (MAPK) family. JNKs mediate cellular responses to stress, infection, and inflammatory stimuli. They regulate apoptosis, differentiation, and cytokine expression. Dysregulation of JNK signaling contributes to inflammatory diseases, cancer, and neurodegeneration. Inhibiting JNK activity enables researchers to dissect MAPK pathway contributions to cell fate, stress response, and immune modulation (Patra et al., 2020).

Mechanism of Action of SP600125

SP600125 is a reversible, ATP-competitive inhibitor targeting the catalytic domain of JNK isoforms. It binds with nanomolar affinity: JNK1 IC₅₀ = 40 nM, JNK2 IC₅₀ = 40 nM, JNK3 IC₅₀ = 90 nM. The compound exhibits a K_i of 190 nM versus recombinant human JNK2 (time-resolved fluorescence assay with GST-c-Jun substrate). SP600125 demonstrates >300-fold selectivity over ERK1 and p38-2 kinases, minimizing off-target MAPK inhibition (APExBIO).

In cellular systems, SP600125 suppresses c-Jun phosphorylation (IC₅₀ = 5–10 μM in Jurkat T cells) and downregulates JNK-dependent transcriptional activity. It inhibits cytokine (IL-2, IFN-γ) expression and modulates inflammatory gene expression in both lymphoid and myeloid cells.

Evidence & Benchmarks

• SP600125 inhibits JNK1 and JNK2 kinase activity with IC₅₀ values of 40 nM each in vitro (APExBIO).
• SP600125 demonstrates >300-fold selectivity for JNK over ERK1 and p38-2 kinases (APExBIO, see product page).
• The compound suppresses c-Jun phosphorylation in Jurkat T cells (IC₅₀ = 5–10 μM) (Patra et al., 2020).
• SP600125 decreases IL-2 and IFN-γ expression in activated T cells, reflecting JNK-regulated transcriptional inhibition (Patra et al., 2020).
• In mouse models, SP600125 reduces LPS-induced TNF-α expression, showing in vivo anti-inflammatory potential (Patra et al., 2020).
• SP600125 modulates CREB-mediated promoter activity in MIN6 cells and inhibits apoptosis in thymocytes in vivo (APExBIO).

Applications, Limits & Misconceptions

SP600125 is widely used in:

• Apoptosis assays in cell lines and animal models
• Inflammation research, especially cytokine expression modulation (IL-2, IFN-γ, TNF-α)
• Cancer research, to dissect MAPK and JNK pathway function
• Neurodegenerative disease models, to examine stress response pathways
• Cell viability, proliferation, and cytotoxicity workflows (see SP600125: ATP-Competitive JNK Inhibitor for Translational...; this article provides a broader mechanistic perspective and updated molecular benchmarks beyond the translational focus of the linked review.)

Common Pitfalls or Misconceptions

• SP600125 is not a pan-MAPK inhibitor; its >300-fold selectivity for JNK over ERK1/p38-2 is well-documented (APExBIO).
• IC₅₀ values depend on assay conditions (substrate, ATP concentration, cell type); always optimize dosing experimentally.
• SP600125 is insoluble in water; improper dissolution may lead to precipitation and loss of potency (APExBIO).
• Long-term storage of working solutions is not recommended; degradation or reduced activity may occur.
• At high concentrations (>20 μM), off-target kinase effects may emerge—interpret data accordingly (see SP600125 (SKU A4604): Reliable JNK Inhibition for Reprodu...; this article expands on concentration-dependent effects and protocol guidance for rigorous use.)

Workflow Integration & Parameters

SP600125 (dibenzo[cd,g]indazol-6(2H)-one, MW 220.23, C₁₄H₈N₂O, CAS 129-56-6) is provided as a solid by APExBIO. It is insoluble in water; dissolve at ≥11 mg/mL in DMSO or ≥2.56 mg/mL in ethanol with gentle warming. Prepare fresh solutions or store aliquots below -20°C for up to several months. Use in biochemical assays (kinase inhibition, time-resolved fluorescence) and cellular assays (phospho-c-Jun blotting, cytokine ELISA). For cell-based research, titrate in the 1–20 μM range, verifying effects on c-Jun phosphorylation and cytokine output. For detailed workflow and troubleshooting, see SP600125 (SKU A4604): Scenario-Driven Solutions for Relia...—this article extends on scenario-based troubleshooting and experimental reproducibility for cell-based MAPK pathway studies.

Conclusion & Outlook

SP600125 remains a gold-standard, selective ATP-competitive JNK inhibitor for dissecting MAPK pathway dynamics in apoptosis, inflammation, and neurobiology. Its robust, reproducible potency and high selectivity support confident data interpretation in both in vitro and in vivo research. Careful attention to solubility, dosing, and assay controls ensures meaningful results. Ongoing advances in JNK pathway targeting and emerging disease models will further expand the utility of SP600125. For comprehensive product details and protocols, refer to the SP600125 product page (APExBIO).